Addressing the Threat of Drug-Resistant Tuberculosis A Realistic Assessment of the Challenge: Workshop Summary (2009) / Chapter Skim
Currently Skimming:
1 Introduction
1 Introduction
Pages 15-18
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 15... ...
Nonetheless, multidrug-resistant TB (MDR TB) is a major and growing global threat.1 An estimated 4.8 percent of all new and previously treated TB cases diagnosed worldwide in 2006 -- a total of 489,139 cases (95 percent confidence level, 455,093–614,215)
|
From page 16... ...
However, even new drugs must be used only in combination, 2 XDR TB is MDR TB that is also resistant to any one of the fluoroquinolones and any one of the second-line injectable drugs. 3 Using MDR TB figures reported in WHO's fourth report on anti-tuberculosis drug resis tance (WHO, 2008b)
|
From page 17... ...
To provide baseline information on MDR TB and outline the issues for discussion during the workshop, the IOM commissioned a white paper from Partners In Health (see Appendix C)
|
From page 18... ...
Only 11 of 22 high-burden TB countries provide data on drug-resistant TB, and even fewer have the capability to assess patients' susceptibility to the second-line drugs used to treat MDR TB. To exploit the opportunity offered by having multiple major stakeholders present at the workshop, she encouraged all participants to engage in a frank discussion of the emerging crisis.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.